Search PubMed⌕ Search

Biomedical subjects

D R Sweeney

Publications and source records attributed to D R Sweeney.

At least 109 records · Page 6Linked to original sources
PubMed1980

The thyroid-stimulating hormone response to thyrotropin-releasing hormone in mania and bipolar depression.

The release of thyroid-stimulating hormone (TSH) from the pituitary after infusion of 500 microgram of thyrotropin-releasing hormone (TRH) was decreased (p < 0.01) in manic patients and increased (p < 0.01) in bipolar depressed patients compared to a control group of patients with personality disorders. These results suggest that the TRH test may be useful in the diagnosis of psychiatric disorders and in the prediction of response to pharmacotherapy. We discuss the role of central monoaminergic systems in changes in the TSH response to TRH.

Affective Disorders, Psychotic↗
PubMed1980

Efficacy of clonidine in opiate withdrawal: a study of thirty patients.

In a placebo-controlled, double-blind crossover trial, clonidine caused a marked and significant reduction of objective signs and subjective symptoms of opiate withdrawal in thirty hospitalized opiate addicts. In an open trial of clonidine in opiate withdrawal, clonidine was found to suppress opiate withdrawal signs and symptoms, allowing all of the patients to detoxify successfully from chronic opiate addiction. Clonidine was demonstrated to reverse and suppress the signs, symptoms, and effects associated with opiate withdrawal. These data support a release from chronic opiate-induced noradrenergic inhibition producing noradrenergic hyperactivity as the pathophysiological substrate for opiate withdrawal. Clonidine replaces opiate-mediated inhibition with alpha-2 mediated inhibition of noradrenergic nuclei.

Brain↗
PubMed1979

Differences between self-reported and observed pleasure in depression and schizophrenia.

Observer ratings of positive affect and self-ratings of pleasurable experience were collected daily on six schizophrenic and five depressed inpatients during baseline medication-free periods ranging from 11 to 27 days. Schizophrenics were observed to display significantly higher degrees of positive affect than depressed patients, but they reported significantly lower degrees of experienced pleasure. Depressed patients, conversely, were observed to demonstrate significantly lower degrees of positive affect than schizophrenics, but they reported significantly higher degrees of experienced pleasure. These results have important implications for the further specification of mechanisms underlying abnormalities in pleasure associated with psychiatric disorders.

Activities of Daily Living↗
PubMed1979

A follow-up neurobiological study: why volunteer?

There is usually great concern over the use of psychiatric patients for clinical research, as it raises the ethical and legal issues of human dignity and autonomy. In this paper the authors describe and evaluate a follow-up neurobiological study of patients who had been discharged from a psychiatric research ward at least ten months earlier. It is pointed out that such studies are rare and that the writers were provided with the unique opportunity to examine attitudinal and motivational dimensions involved in the patients' agreement to participate in the study.

Affective Symptoms↗
PubMed1979

Endorphin-locus coeruleus connection mediates opiate action and withdrawal.

Endorphins and exogenous opiates inhibit the activity of the noradrenergic nucleus locus coeruleus (LC). This discovery of endorphin transmitters and their interaction with the LC has supported our studies which have suggested that the majority of the signs and symptoms of opiate withdrawal are mimicked by electrical or chemical activation of the LC. We hypothesize that this endorphin-LC connection is critical to opiate action and the withdrawal syndrome. This hypothesis suggests that chronic opiate administration inhibits LC activity and that opiate abstinence after addiction results in a release from inhibition with resultant LC hyperactivity. This hypothesis is supported by recent data suggesting that clonidine as a drug which inhibits the LC and LC-mediated noradrenergic activation, is an efficacious non-opiate treatment for opiate withdrawal. This hypothesis can be tested in man by evaluating drugs which inhibit the LC and LC-mediated behaviors for anti-withdrawal efficacy.

Adrenergic Fibers↗